cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.8267975
title: Supplementary Material for: Cross-Sectional Area Analysis of the Head of the Caudate Nucleus in Huntington’s Disease

description: <b><i>Background:</i></b> Caudate nucleus atrophy is a well-known neuroimaging feature of Huntington’s disease (HD). Some researchers have reported a decrease in the volume of the striatum on magnetic resonance images (MRIs) even in the presymptomatic stage of the disease. Despite the many neuroimaging studies on HD, the optimal method for measuring the caudate nucleus area on MRIs and the most effective cutoff values for diagnosing HD remain unclear. <b><i>Objectives and Methods:</i></b> To define suitable imaging sequences and cutoff values for HD, we measured the area of the head of the caudate nucleus (HCN) in 11 patients with HD, 22 age- and sex-matched individuals without neurodegenerative disorders in the central nervous system, 22 sex-matched patients with Alzheimer’s disease, 22 sex-matched patients with Parkinson’s disease, and 7 patients with dentatorubral-pallidoluysian atrophy. <b><i>Results:</i></b> On T2-weighted images (T2WIs), we found significantly reduced HCN area at the rostral level in individuals with HD relative to those of the individuals in the other groups. A significant inverse correlation (ρ = –0.61, <i>p</i> = 0.046) was observed between the HD duration and HCN area at the rostral slice level on T2WIs. The cutoff value for distinguishing patients with HD from healthy individuals and those with other neurodegenerative diseases was 85 mm<sup>2</sup> at the rostral level on T2WIs (100% sensitivity and specificity). <b><i>Conclusions:</i></b> This cutoff value can be applied clinically to evaluate brain atrophy in HD. Our method is advantageous because it is simple and can be implemented easily in daily clinical practice.
DOI: 10.6084/m9.figshare.8267927
title: codeBones.zip from Simultaneous elastic shape optimization for a domain splitting in bone tissue engineering

description: Numerical code used to derive the optimal microstructure designs.
DOI: 10.6084/m9.figshare.8267915
title: Table S1 from Exploring the lower thermal limits for development of the human malaria parasite, <i>Plasmodium falciparum</i>

description: Summary of compiled low temperature experiments using An. stephensi and An. gambiae mosquitoes and Plasmodium falciparum NF54. Data are grouped for independent replicate feeds.
DOI: 10.6084/m9.figshare.8267927.v1
title: codeBones.zip from Simultaneous elastic shape optimization for a domain splitting in bone tissue engineering

description: Numerical code used to derive the optimal microstructure designs.
DOI: 10.6084/m9.figshare.8267906
title: Ge_JGR_Oceans_CBS_Storm

description: Datasets for Ge's JGR-Ocean submission of CBS work
DOI: 10.6084/m9.figshare.8267915.v1
title: Table S1 from Exploring the lower thermal limits for development of the human malaria parasite, <i>Plasmodium falciparum</i>

description: Summary of compiled low temperature experiments using An. stephensi and An. gambiae mosquitoes and Plasmodium falciparum NF54. Data are grouped for independent replicate feeds.
DOI: 10.6084/m9.figshare.8267906.v2
title: Ge_JGR_Oceans_CBS_Storm

description: Datasets for Ge's JGR-Ocean submission of CBS work
DOI: 10.6084/m9.figshare.8267906.v1
title: Ge_JGR_Oceans_CBS_Storm

description: Datasets for Ge's JGR-Ocean submission of CBS work
DOI: 10.6084/m9.figshare.8267663
title: Supplementary Material for: Kooperation in der Versorgung psychischer Störungen aus hausärztlicher, fachärztlicher und fachpsychotherapeutischer Perspektive

description: <b><i>Hintergrund:</i></b> Die Kooperation von Hausärzten mit ambulant und stationär tätigen Spezialisten ist in der Versorgung bei psychischen Störungen von zentraler Bedeutung. Empirische Studien zum aktuellen Kooperationsgeschehen fehlen. Ziel war die Analyse der Zusammenarbeit von hausärztlichen, fachärztlichen und psychologisch-psychotherapeutischen Behandlern in der ambulanten und stationären Versorgung. <b><i>Methode:</i></b> Mittels eines Online- und postali­schen Fragebogens wurden Kooperationsformen, Probleme in der Kooperation, Kooperationsbedarf, Zufriedenheit und Verbesserungsvorschläge zur Vernetzung erhoben. <b><i>Ergebnisse:</i></b> Insgesamt füllten <i>N</i> = 504 Behandler den Fragebogen aus, darunter 108 Hausärzte, 96 ambulant und 63 stationär tätige Fachärzte sowie 216 ambulant und 21 stationär tätige psychologische Psychotherapeuten. Kooperation findet in erster Linie bei Bedarf im Einzelfall statt und basiert nur wenig auf festgelegten Strukturen und definierten Routi­nen. Obwohl sich die Teilnehmenden relativ zufrieden mit der aktuellen Kooperation zeigen, ist der wahrgenommene Bedarf an Kooperation groß. Schwierigkeiten werden v.a. aufgrund von fehlenden ambulanten Therapieplätzen, Zeitmangel, Problemen bei der Erreichbarkeit von Kollegen und wenig etablierten Kooperationsprozessen gesehen. <b><i>Implikationen:</i></b> Die Behandler sind grundsätzlich zufrieden, sehen aber dennoch Verbesserungsbedarf bei der Vernetzung der psychischen Versorgung. Daher ist die Optimie­rung entsprechender Strukturen und Prozesse mit dem Ziel der Verbesserung der patientenorientierten Behandlung von Menschen mit psychischen Störungen notwendig.
DOI: 10.6084/m9.figshare.8267663.v1
title: Supplementary Material for: Kooperation in der Versorgung psychischer Störungen aus hausärztlicher, fachärztlicher und fachpsychotherapeutischer Perspektive

description: <b><i>Hintergrund:</i></b> Die Kooperation von Hausärzten mit ambulant und stationär tätigen Spezialisten ist in der Versorgung bei psychischen Störungen von zentraler Bedeutung. Empirische Studien zum aktuellen Kooperationsgeschehen fehlen. Ziel war die Analyse der Zusammenarbeit von hausärztlichen, fachärztlichen und psychologisch-psychotherapeutischen Behandlern in der ambulanten und stationären Versorgung. <b><i>Methode:</i></b> Mittels eines Online- und postali­schen Fragebogens wurden Kooperationsformen, Probleme in der Kooperation, Kooperationsbedarf, Zufriedenheit und Verbesserungsvorschläge zur Vernetzung erhoben. <b><i>Ergebnisse:</i></b> Insgesamt füllten <i>N</i> = 504 Behandler den Fragebogen aus, darunter 108 Hausärzte, 96 ambulant und 63 stationär tätige Fachärzte sowie 216 ambulant und 21 stationär tätige psychologische Psychotherapeuten. Kooperation findet in erster Linie bei Bedarf im Einzelfall statt und basiert nur wenig auf festgelegten Strukturen und definierten Routi­nen. Obwohl sich die Teilnehmenden relativ zufrieden mit der aktuellen Kooperation zeigen, ist der wahrgenommene Bedarf an Kooperation groß. Schwierigkeiten werden v.a. aufgrund von fehlenden ambulanten Therapieplätzen, Zeitmangel, Problemen bei der Erreichbarkeit von Kollegen und wenig etablierten Kooperationsprozessen gesehen. <b><i>Implikationen:</i></b> Die Behandler sind grundsätzlich zufrieden, sehen aber dennoch Verbesserungsbedarf bei der Vernetzung der psychischen Versorgung. Daher ist die Optimie­rung entsprechender Strukturen und Prozesse mit dem Ziel der Verbesserung der patientenorientierten Behandlung von Menschen mit psychischen Störungen notwendig.
DOI: 10.6084/m9.figshare.8267645
title: Supplementary Material for: Towards a Rational and Efficient Diagnostic Approach in Children Referred for Growth Failure to the General Paediatrician

description: Based on a recent Dutch national guideline, we propose a structured stepwise diagnostic approach for children with growth failure (short stature and/or growth faltering), aiming at high sensitivity for pathologic causes at acceptable specificity. The first step is a detailed clinical assessment, aiming at obtaining relevant clinical clues from the medical history (including family history), physical examination (emphasising head circumference, body proportions and dysmorphic features) and assessment of the growth curve. The second step consists of screening: a radiograph of the hand and wrist (for bone age and assessment of anatomical abnormalities suggestive for a skeletal dysplasia) and laboratory tests aiming at detecting disorders that can present as isolated short stature (anaemia, growth hormone deficiency, hypothyroidism, coeliac disease, renal failure, metabolic bone diseases, renal tubular acidosis, inflammatory bowel disease, Turner syndrome [TS]). We advise molecular array analysis rather than conventional karyotyping for short girls because this detects not only TS but also copy number variants and uniparental isodisomy, increasing diagnostic yield at a lower cost. Third, in case of diagnostic clues for primary growth disorders, further specific testing for candidate genes or a hypothesis-free approach is indicated; suspicion of a secondary growth disorder warrants adequate further targeted testing.
DOI: 10.6084/m9.figshare.8267645.v1
title: Supplementary Material for: Towards a Rational and Efficient Diagnostic Approach in Children Referred for Growth Failure to the General Paediatrician

description: Based on a recent Dutch national guideline, we propose a structured stepwise diagnostic approach for children with growth failure (short stature and/or growth faltering), aiming at high sensitivity for pathologic causes at acceptable specificity. The first step is a detailed clinical assessment, aiming at obtaining relevant clinical clues from the medical history (including family history), physical examination (emphasising head circumference, body proportions and dysmorphic features) and assessment of the growth curve. The second step consists of screening: a radiograph of the hand and wrist (for bone age and assessment of anatomical abnormalities suggestive for a skeletal dysplasia) and laboratory tests aiming at detecting disorders that can present as isolated short stature (anaemia, growth hormone deficiency, hypothyroidism, coeliac disease, renal failure, metabolic bone diseases, renal tubular acidosis, inflammatory bowel disease, Turner syndrome [TS]). We advise molecular array analysis rather than conventional karyotyping for short girls because this detects not only TS but also copy number variants and uniparental isodisomy, increasing diagnostic yield at a lower cost. Third, in case of diagnostic clues for primary growth disorders, further specific testing for candidate genes or a hypothesis-free approach is indicated; suspicion of a secondary growth disorder warrants adequate further targeted testing.
DOI: 10.6084/m9.figshare.8267588
title: Supplementary Material for: Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer

description: <b><i>Objectives:</i></b> This study aimed to evaluate whether a decrease of computed tomography (CT) value for tumors serves as a predictive marker in patients with advanced gastric cancer (aGC) who have undergone chemotherapy with vascular epithelial growth factor receptor 2 inhibitor (ramucirumab). <b><i>Method:</i></b> We retrospectively analyzed 44 patients with aGC who received taxane alone (TAX arm; <i>n</i> = 33), ramucirumab alone, or ramucirumab in combination with taxane (RAM arm; <i>n</i> = 11) as second-line or later chemotherapy between July 2010 and October 2016. In all patients, tumor size and tumor CT value were evaluated at two timepoints: pretreatment and first evaluation. We calculated the change of the tumors’ CT value. The associations of these factors with tumor response, progression-free survival (PFS), and overall survival were investigated. <b><i>Results:</i></b> Ten (90.9%) of 11 patients in the RAM arm and 18 (54.5%) of 33 patients in the TAX arm showed decreased CT values. The rate of CT value change in the RAM arm (median −32.80%, range −53.63 to 6.84%) was higher than that in the TAX arm (median −0.44%, range −37.47 to 40.64%; <i>p</i> = 0.0005). When using the median value of CT value change as a cut-off, PFS was significantly longer in patients with a high rate of CT value change (decrease ≥32.80%) than in those with a low rate (decrease &lt;32.80%) in the RAM arm (median 292 and 112 days; <i>p</i> = 0.045), while no significant difference of this kind was found in the TAX arm (median 91 and 125 days; <i>p</i> = 0.45). <b><i>Conclusions:</i></b> Patients with aGC treated with ramucirumab experienced a significant decrease of CT value of tumors and had an association between the rate of CT value change and PFS. Our study suggests that CT value changes of tumors may be a predictor for the efficacy of ramucirumab in aGC.
DOI: 10.6084/m9.figshare.8267588.v1
title: Supplementary Material for: Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer

description: <b><i>Objectives:</i></b> This study aimed to evaluate whether a decrease of computed tomography (CT) value for tumors serves as a predictive marker in patients with advanced gastric cancer (aGC) who have undergone chemotherapy with vascular epithelial growth factor receptor 2 inhibitor (ramucirumab). <b><i>Method:</i></b> We retrospectively analyzed 44 patients with aGC who received taxane alone (TAX arm; <i>n</i> = 33), ramucirumab alone, or ramucirumab in combination with taxane (RAM arm; <i>n</i> = 11) as second-line or later chemotherapy between July 2010 and October 2016. In all patients, tumor size and tumor CT value were evaluated at two timepoints: pretreatment and first evaluation. We calculated the change of the tumors’ CT value. The associations of these factors with tumor response, progression-free survival (PFS), and overall survival were investigated. <b><i>Results:</i></b> Ten (90.9%) of 11 patients in the RAM arm and 18 (54.5%) of 33 patients in the TAX arm showed decreased CT values. The rate of CT value change in the RAM arm (median −32.80%, range −53.63 to 6.84%) was higher than that in the TAX arm (median −0.44%, range −37.47 to 40.64%; <i>p</i> = 0.0005). When using the median value of CT value change as a cut-off, PFS was significantly longer in patients with a high rate of CT value change (decrease ≥32.80%) than in those with a low rate (decrease &lt;32.80%) in the RAM arm (median 292 and 112 days; <i>p</i> = 0.045), while no significant difference of this kind was found in the TAX arm (median 91 and 125 days; <i>p</i> = 0.45). <b><i>Conclusions:</i></b> Patients with aGC treated with ramucirumab experienced a significant decrease of CT value of tumors and had an association between the rate of CT value change and PFS. Our study suggests that CT value changes of tumors may be a predictor for the efficacy of ramucirumab in aGC.
DOI: 10.6084/m9.figshare.8267483
title: Supplementary Material for: The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines

description: Metastatic neuroendocrine cancer still constitutes a palliative situation, lacking promising treatment options. Oncolytic virotherapy, a novel type of virus-based immunotherapy, lyses tumor cells using genetically engineered viruses thereby activating the immune system to induce an optimized antitumor response which could bring down tumor masses to a stage of minimal residual tumor disease. The oncolytic vector talimogene laherparepvec (T-VEC, herpes simplex virus [HSV] type 1) has already shown excellent safety profiles in clinical studies and has become the first ever FDA/EMA-approved oncolytic virus (OV). This work presents a first preclinical assessment of this state-of-the-art OV, using a panel of human neuroendocrine tumor/neuroendocrine carcinoma (NET/NEC) cell lines. Cytotoxicity, transgene expression, and viral replication patterns were studied. Furthermore, the antiproliferative activity was compared to the one of mTOR inhibitor Everolimus and also interactions between the OV and Everolimus were evaluated. Moreover, virostatic effects of ganciclovir (GCV) on replication of T-VEC were assessed and electron microscopic pictures were taken to comprehend viral envelopment and details of the replication cycle of T-VEC in human neuroendocrine cancer. It could be shown that T-VEC infects, replicates in, and lyses human NET/NEC cells exhibiting high oncolytic efficiencies already at quite low virus concentrations. Interestingly, Everolimus was not found to have any relevant impact on rates of viral replication, but no additive effects could be proved using a combinatorial therapy regimen. On the other hand, GCV was shown to be able to limit replication of T-VEC, thus establishing an important safety feature for future treatments of NET/NEC patients. Taken together, T-VEC opens up a promising novel treatment option for NET/NEC patients, warranting its further preclinical and clinical development.
DOI: 10.6084/m9.figshare.8267483.v1
title: Supplementary Material for: The Oncolytic Herpes Simplex Virus Talimogene Laherparepvec Shows Promising Efficacy in Neuroendocrine Cancer Cell Lines

description: Metastatic neuroendocrine cancer still constitutes a palliative situation, lacking promising treatment options. Oncolytic virotherapy, a novel type of virus-based immunotherapy, lyses tumor cells using genetically engineered viruses thereby activating the immune system to induce an optimized antitumor response which could bring down tumor masses to a stage of minimal residual tumor disease. The oncolytic vector talimogene laherparepvec (T-VEC, herpes simplex virus [HSV] type 1) has already shown excellent safety profiles in clinical studies and has become the first ever FDA/EMA-approved oncolytic virus (OV). This work presents a first preclinical assessment of this state-of-the-art OV, using a panel of human neuroendocrine tumor/neuroendocrine carcinoma (NET/NEC) cell lines. Cytotoxicity, transgene expression, and viral replication patterns were studied. Furthermore, the antiproliferative activity was compared to the one of mTOR inhibitor Everolimus and also interactions between the OV and Everolimus were evaluated. Moreover, virostatic effects of ganciclovir (GCV) on replication of T-VEC were assessed and electron microscopic pictures were taken to comprehend viral envelopment and details of the replication cycle of T-VEC in human neuroendocrine cancer. It could be shown that T-VEC infects, replicates in, and lyses human NET/NEC cells exhibiting high oncolytic efficiencies already at quite low virus concentrations. Interestingly, Everolimus was not found to have any relevant impact on rates of viral replication, but no additive effects could be proved using a combinatorial therapy regimen. On the other hand, GCV was shown to be able to limit replication of T-VEC, thus establishing an important safety feature for future treatments of NET/NEC patients. Taken together, T-VEC opens up a promising novel treatment option for NET/NEC patients, warranting its further preclinical and clinical development.
DOI: 10.6084/m9.figshare.8267510.v1
title: A high-resolution map of Singapore’s terrestrial ecosystems

description: A high-resolution map of Singapore’s terrestrial ecosystems. To the reviewers from Data Journal, this is the supplementary material for Figure 1.
DOI: 10.6084/m9.figshare.8267441
title: de novo genome assembly tutorial

description: data for the tutorial found here: https://astrobiomike.github.io/genomics/de_novo_assembly
DOI: 10.6084/m9.figshare.8267441.v1
title: de novo genome assembly tutorial

description: data for the tutorial found here: https://astrobiomike.github.io/genomics/de_novo_assembly
DOI: 10.6084/m9.figshare.8267510.v2
title: A high-resolution map of Singapore’s terrestrial ecosystems

description: A high-resolution map of Singapore’s terrestrial ecosystems. To the reviewers from Data Journal, this is the supplementary material for Figure 1.
DOI: 10.6084/m9.figshare.8267510.v3
title: A high-resolution map of Singapore’s terrestrial ecosystems

description: A high-resolution map of Singapore’s terrestrial ecosystems. The dataset is described in the accompanying data descriptor article, available here: https://www.mdpi.com/2306-5729/4/3/116 Please reference this article when using the dataset.
DOI: 10.6084/m9.figshare.8267210
title: Additional file 14: of Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis

description: Dataset. Dataset used for analyses. (CSV 166 kb)
DOI: 10.6084/m9.figshare.8267210.v1
title: Additional file 14: of Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis

description: Dataset. Dataset used for analyses. (CSV 166 kb)
DOI: 10.6084/m9.figshare.8267192
title: Additional file 9: of The impact of skin care products on skin chemistry and microbiome dynamics

description: Table S8. feature table with Probabilistic quotient normalization for molecularâ microbial analysis. (ZIP 29557 kb)
DOI: 10.6084/m9.figshare.8267189
title: Additional file 8: of The impact of skin care products on skin chemistry and microbiome dynamics

description: Table S7. Metadata for Calour analysis. (TXT 129 kb)
DOI: 10.6084/m9.figshare.8267183
title: MOESM3 of A perfusion bioreactor-based 3D model of the subarachnoid space based on a meningeal tissue construct

description: Additional file 3: Figure S3. Gene ontology (GO) analysis of RNA sequencing. GO analysis of 980 differentially regulated genes sorted according to Process (A), Component (B) and Function (C). q-value indicating GO-term enrichment.
DOI: 10.6084/m9.figshare.8267189.v1
title: Additional file 8: of The impact of skin care products on skin chemistry and microbiome dynamics

description: Table S7. Metadata for Calour analysis. (TXT 129 kb)
DOI: 10.6084/m9.figshare.8267192.v1
title: Additional file 9: of The impact of skin care products on skin chemistry and microbiome dynamics

description: Table S8. feature table with Probabilistic quotient normalization for molecularâ microbial analysis. (ZIP 29557 kb)
DOI: 10.6084/m9.figshare.8267180
title: Additional file 7: of The impact of skin care products on skin chemistry and microbiome dynamics

description: Table S6. Feature table for Calour analysis. (CSV 91651 kb)
DOI: 10.6084/m9.figshare.8267183.v1
title: MOESM3 of A perfusion bioreactor-based 3D model of the subarachnoid space based on a meningeal tissue construct

description: Additional file 3: Figure S3. Gene ontology (GO) analysis of RNA sequencing. GO analysis of 980 differentially regulated genes sorted according to Process (A), Component (B) and Function (C). q-value indicating GO-term enrichment.
DOI: 10.6084/m9.figshare.8267171
title: Additional file 6: of The impact of skin care products on skin chemistry and microbiome dynamics

description: Table S5. Feature table for individual feature abundance in armpits. (XLSX 379 kb)
DOI: 10.6084/m9.figshare.8267180.v1
title: Additional file 7: of The impact of skin care products on skin chemistry and microbiome dynamics

description: Table S6. Feature table for Calour analysis. (CSV 91651 kb)
DOI: 10.6084/m9.figshare.8267171.v1
title: Additional file 6: of The impact of skin care products on skin chemistry and microbiome dynamics

description: Table S5. Feature table for individual feature abundance in armpits. (XLSX 379 kb)
DOI: 10.6084/m9.figshare.8267156
title: Additional file 5: of The impact of skin care products on skin chemistry and microbiome dynamics

description: Table S4. Feature table for statistical analysis with blank filtering and total ion current normalization. (CSV 150242 kb)
DOI: 10.6084/m9.figshare.8267150
title: Additional file 4: of The impact of skin care products on skin chemistry and microbiome dynamics

description: Table S3. Mzmine feature finding and crop filtering parameters. (XLSX 4 kb)
DOI: 10.6084/m9.figshare.8267150.v1
title: Additional file 4: of The impact of skin care products on skin chemistry and microbiome dynamics

description: Table S3. Mzmine feature finding and crop filtering parameters. (XLSX 4 kb)
DOI: 10.6084/m9.figshare.8267156.v1
title: Additional file 5: of The impact of skin care products on skin chemistry and microbiome dynamics

description: Table S4. Feature table for statistical analysis with blank filtering and total ion current normalization. (CSV 150242 kb)